Replies to post #282142 on Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

In Leo's last PR he stated the overall GI market was expected to grow to $48B in 2022.

The top selling drugs (Humira, Stelara, Remicade) in this market are immuno-suppressant, injectable biologics with side effects that include infections, cancer and death.

If Brilacidin is proven to be a safer, less toxic, more effective, orally administered drug (the evidence is growing) then YES, I think Brilacidin will ultimately gain 31% ($15B) or more of the GI market.

Message in reply to:
Any chance of this being a $15 Billion performer ?